Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	5.91M 0 5.17M 4.77M 4.39M 8.28M 569M 8.46M 56.97M 22.41M 279M 22.2M 21.71M 960M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.91M 0 5.17M 4.77M 4.39M 8.28M 569M 8.46M 56.97M 22.41M 279M 22.2M 21.71M 960M	EV / Sales 2026 *	3.98x	EV / Sales 2027 *	2.27x
Free-Float	82.9%	Yield 2026 *	-	Yield 2027 *	-

07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
05-20	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
05-18	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
04-24	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
04-02	Evogene reports receipt of Nasdaq minimum bid price notification	RE
04-02	Evogene Gets Nasdaq Minimum Bid Price Notification	MT
03-05	Evogene Ltd., Q4 2025 Earnings Call, Mar 05, 2026
03-05	Evogene Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
01/12/20	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

07-08	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
06-02	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
05-20	Evogene : Q1 2026 Consolidated Financial Statements	PU
05-20	Evogene: Q1 Earnings Snapshot	AQ
05-20	Evogene Reports First Quarter 2026 Financial Results	PR

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	30/11/2004
Polina Ravzin PRN	Corporate Officer/Principal	-	31/12/2021
Olga Nissan PRN	Corporate Officer/Principal	-	31/12/2025

Evogene Ltd Share Price TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news : Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	02/06/2010
Sarit Firon CHM	Chairman	60	31/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	5.91M
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+386.06%	+593.85%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+5.93%	+60.25%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+28.41%	-8.01%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.38%	+34.38%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+72.42%	+115.55%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+14.54%	+19.16%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+18.43%	-30.79%	13.02B
ABIVAX	-0.08%	-3.01%	+1,282.83%	+635.80%	11.76B
Average	+0.13%	+0.04%	+226.37%	+177.52%	22.91B
Weighted average by Cap.	+0.24%	+0.36%	+174.57%	+186.15%

	2026 *	2027 *
Net sales	1.48M 0 1.3M 1.2M 1.1M 2.08M 143M 2.13M 14.3M 5.63M 69.99M 5.57M 5.45M 241M	2.6M 0 2.27M 2.1M 1.93M 3.64M 250M 3.72M 25.06M 9.86M 123M 9.76M 9.55M 422M
Net income	-16.69M -0 -14.58M -13.46M -12.4M -23.38M -1.61B -23.9M -161M -63.26M -787M -62.67M -61.29M -2.71B	-13.92M -0 -12.16M -11.22M -10.34M -19.49M -1.34B -19.93M -134M -52.75M -656M -52.26M -51.11M -2.26B
Net Debt	-	-